Industry Biopharmaceutical
Sector New drug discovery
Fiscal year end September 30
Shares issued and outstanding 52,650,521 *
Stock purchase warrants 357,500 **
Stock options 8,461,266 **
Fully diluted 60,328,637**
Cash  $21.2 million**
Debt Nil**
Trading symbol AVXL
52-week range $4.09 – $1.25*
Financial statements and filings Anavex’s filings can be found on EDGAR.
Investor relations 1-844-689-3939
ir@anavex.com
Transfer agent Nevada Agency and Trust
50 West Liberty Street, Suite 880
Reno, Nevada 89501
Tel: (775) 322-0626
Fax: (775) 322-5623
Transfer agent email: info@natco.org
Resident Agent email: corpserve@natco.org
Web site: www.natco.org
* As at August 7, 2019
** As at June 30, 2019

Forms – Reverse Stock Split
Internal Revenue Service (United States) – Form 8937.
Form_8937_(signed)